drugset / Trial / NCT02947113

Combination of Platinum Doublets and Hypofractionated Radiotherapy in NSCLC

NCT02947113 ↗

NaSingle-groupOpen-labelTreatment

Summary

Concurrent chemoradiotherapy is the standard treatment for locally advanced non-small cell lung carcinoma (NSCLC). Different chemotherapy and radiation regimens have been advocated but in general, cisplatin-doublets are deemed standard of care. Decreasing the overall treatment time of irradiation by hypofractionation is thought to increase the efficacy. Extensive experience is available on the combination of daily-dose cisplatin in combination with hypofractionated radiotherapy. However, no data is available on the safety of cisplatin doublets and hypofractionated radiotherapy

Timeline

Start
2017-11
Primary completion
2017-11
Completion
2017-11

Outcome

Outcome not reported

Stopped (Enrollment): “New studies available with immunotherapy so recruitment is no longer acceptable.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 75 mg/m2 —
Subject Etoposide Small molecule 100 mg/m2 —
Subject Pemetrexed Small molecule 500 mg/m2 —